An Open-label, Randomized, 2-treatment, 2-period, Crossover Study to Evaluate the Effect of Probenecid on the Pharmacokinetics of Pexidartinib in Healthy Subjects

Trial Profile

An Open-label, Randomized, 2-treatment, 2-period, Crossover Study to Evaluate the Effect of Probenecid on the Pharmacokinetics of Pexidartinib in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Pexidartinib (Primary) ; Probenecid
  • Indications Breast cancer; Colorectal cancer; Gastrointestinal stromal tumours; Glioblastoma; Malignant melanoma; Pancreatic cancer; Peripheral nervous system diseases; Pigmented villonodular synovitis; Prostate cancer; Sarcoma; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Daiichi Sankyo Inc
  • Most Recent Events

    • 05 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top